🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 46 of 173

  1. US 10828255

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10828289

    Hair follicle stem cell activation and hair growth

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10828326

    Compositions and methods for treating and preventing venom related poisoning

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10829427

    Naphthoquinones, pro-drugs, and methods of use thereof

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10828414

    Magnetic filtration devices and methods related thereto

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10829488

    N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10829518

    Peptide compositions and methods of use

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10822427

    Anti-CSPG4 fusions with interferon for the treatment of malignancy

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10822353

    Dithio ETP derivatives

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10822299

    Compounds and methods for hematopoietic regeneration

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10821178

    Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10822585

    Compositions and methods for treating retinal diseases

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10821190

    HIV peptide vaults and methods of making and using thereof

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10822340

    Substituted imidazolopyrazine compounds and methods of using same

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10821134

    BK virus specific T cells

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10822387

    Binding-triggered transcriptional switches and methods of use thereof

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10821117

    Estrogen therapy for brain gray matter atrophy and associated disability

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10814013

    Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10813956

    Methods for making and using antimicrobial peptides

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10815271

    Structure-based peptide inhibitors of alpha-synuclein aggregation

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10815484

    Compositions and methods for treating cancer

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10813917

    Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10815219

    2,4-diaminoquinazoline derivatives for inhibiting endoplasmic reticulum (ER) stress

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10813894

    Methods of inhibiting pain

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10814010

    FOXC2 inhibitor and methods of use thereof

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10813909

    Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10806763

    Compositions of polymeric myrcene

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10806702

    Bis-polymer lipid-peptide conjugates and nanoparticles thereof

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10806807

    TCO conjugates and methods for delivery of therapeutic agents

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10807951

    mTORC1 modulators

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10808230

    Selection methods for genetically-modified T cells

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10800769

    Heterocyclic inhibitors of ATR kinase

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10799573

    Pertussis vaccines and methods of making and using

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10799567

    Yeast-based immunotherapy and type I interferon sensitivity

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10800774

    Heterocyclic inhibitors of ATR kinase

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10800749

    Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10801030

    General secretory pathway (GSP) mutant listeria SPP., and methods for making and using the same

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10799511

    Methods for reducing or ameliorating mortality and/or morbidity due to chlorine inhalation

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10799466

    Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10799512

    Estrogen combination for treatment of multiple sclerosis

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10799576

    RSV vaccines and methods of production and use thereof

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10799620

    Ring and tubular structures and methods of synthesis and use thereof

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10800797

    Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10792287

    Methods for treating mitochondrial diseases

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10793846

    Compositions and methods for treating celiac sprue disease

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10793884

    Methods and materials for making simvastatin and related compounds

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10793878

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10793595

    Toll-like receptor 2 ligands and methods of making and using thereof

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.